ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca, Celltrion and Daiichi Sankyo side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

AstraZeneca×Celltrion×Daiichi Sankyo×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaCelltrionDaiichi Sankyo
studies on the registry4,19784499
open to participants now298437
phase 3 studies under way200521
reach primary completion within a year168611
programswith a study of their own in two years119+5 named only1520

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaCelltrionDaiichi Sankyo
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Celltrion: 6 of its 15 programs at phase 1

  1. ixekizumabphase 1
  2. L03RD1phase 1
  3. L03RD2phase 1
  4. CT-P52phase 1
  5. CTL02phase 1

and 1 more — sign in to see them all

40%

Daiichi Sankyo: 7 of its 20 programs at phase 1

  1. DS1025Aphase 1
  2. DS3610Aphase 1
  3. DS5361Bphase 1
  4. DS9051Bphase 1
  5. valemetostatphase 1

and 2 more — sign in to see them all

35%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%
00%25%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Celltrion: 9 of its 15 programs at phase 3

  1. CT-P55phase 3
  2. CT-P51phase 3
  3. daratumumabphase 3
  4. empagliflozinphase 3
  5. CT-P43phase 3

and 4 more — sign in to see them all

60%

Daiichi Sankyo: 4 of its 20 programs at phase 3

  1. trastuzumab deruxtecanphase 3
  2. datopotamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. raludotatug deruxtecanphase 3
20%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%
00%

Daiichi Sankyo: 4 of its 20 programs at approved, new studies

  1. quizartinibapproved, new study
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study
20%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Celltrion3 readouts · 3 phase 3·

Celltrion, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. empagliflozinphase 3 · Dec 0 · NCT07093476
·

Celltrion, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. CT-P51phase 3 · Feb 0 · NCT06939595

Celltrion, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. daratumumabphase 3 · Mar 8 · NCT06952478
·······
Daiichi Sankyo3 readouts · 1 phase 3·

Daiichi Sankyo, Dec ’26: 1 program whose next study reaches primary completion

  1. raludotatug deruxtecanphase 3 · Dec 30 · NCT04707248
····

Daiichi Sankyo, May ’27: 1 program whose next study reaches primary completion

  1. quizartinibapproved, new study · May 1 · NCT03793478
····

Daiichi Sankyo, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. trastuzumab deruxtecanphase 3 · Oct 1 · NCT05950945
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Celltrion

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Daiichi Sankyo

New programs 1

  • olomorasibphase 2 · first study · Oct 16 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 35 in all. A program counts in each condition its studies name most.

ConditionAstraZenecaCelltrionDaiichi Sankyo
Carcinoma, Non-Small-Cell Lungall three · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Celltrion in Carcinoma, Non-Small-Cell Lung: 1 program

  1. CT-P51phase 3

Their studies: Celltrion’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 2all three · compare here

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Celltrion in Diabetes Mellitus, Type 2: 4 programs

  1. empagliflozinphase 3
  2. L03RD1phase 1
  3. L03RD2phase 1
  4. L03TD1phase 1

Their studies: Celltrion’s studies of Diabetes Mellitus, Type 2 in search

Daiichi Sankyo in Diabetes Mellitus, Type 2: 1 program

  1. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Diabetes Mellitus, Type 2 in search

Hyperlipidemiasall three · compare here

AstraZeneca in Hyperlipidemias: 3 programs

  1. laroprovstatphase 3
  2. Laroprovstat/ezetimibe FCDP-slow variantphase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hyperlipidemias in search

Celltrion in Hyperlipidemias: 3 programs

  1. rosuvastatinphase 3
  2. Amlodipinephase 3
  3. Ezetimibephase 3

Their studies: Celltrion’s studies of Hyperlipidemias in search

Daiichi Sankyo in Hyperlipidemias: 4 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Hyperlipidemias in search

Hypercholesterolemiaall three · compare here

AstraZeneca in Hypercholesterolemia: 2 programs

  1. laroprovstatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypercholesterolemia in search

Celltrion in Hypercholesterolemia: 3 programs

  1. rosuvastatinphase 3
  2. Amlodipinephase 3
  3. Ezetimibephase 3

Their studies: Celltrion’s studies of Hypercholesterolemia in search

Daiichi Sankyo in Hypercholesterolemia: 4 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Hypercholesterolemia in search

Dyslipidemiasall three · compare here

AstraZeneca in Dyslipidemias: 3 programs

  1. laroprovstatphase 3
  2. AZD4954phase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Dyslipidemias in search

Celltrion in Dyslipidemias: 1 program

  1. rosuvastatinphase 3

Their studies: Celltrion’s studies of Dyslipidemias in search

Daiichi Sankyo in Dyslipidemias: 3 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study
  3. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Dyslipidemias in search

Hypertensionall three · compare here

AstraZeneca in Hypertension: 2 programs

  1. baxdrostatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypertension in search

Celltrion in Hypertension: 3 programs

  1. rosuvastatinphase 3
  2. Amlodipinephase 3
  3. Ezetimibephase 3

Their studies: Celltrion’s studies of Hypertension in search

Daiichi Sankyo in Hypertension: 2 programs

  1. rosuvastatinphase 1
  2. Ezetimibeapproved, new study

Their studies: Daiichi Sankyo’s studies of Hypertension in search

Atherosclerosisall three · compare here

AstraZeneca in Atherosclerosis: 3 programs

  1. laroprovstatphase 3
  2. baxdrostatphase 3
  3. Berzanoflastphase 2

Their studies: AstraZeneca’s studies of Atherosclerosis in search

Celltrion in Atherosclerosis: 1 program

  1. Ezetimibephase 3

Their studies: Celltrion’s studies of Atherosclerosis in search

Daiichi Sankyo in Atherosclerosis: 1 program

  1. Ezetimibeapproved, new study

Their studies: Daiichi Sankyo’s studies of Atherosclerosis in search

Coronary Artery Diseaseall three · compare here

AstraZeneca in Coronary Artery Disease: 1 program

  1. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Coronary Artery Disease in search

Celltrion in Coronary Artery Disease: 1 program

  1. rosuvastatinphase 3

Their studies: Celltrion’s studies of Coronary Artery Disease in search

Daiichi Sankyo in Coronary Artery Disease: 2 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study

Their studies: Daiichi Sankyo’s studies of Coronary Artery Disease in search

Prostatic Neoplasms2 of 3 · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

–

Daiichi Sankyo in Prostatic Neoplasms: 1 program

  1. valemetostatphase 1

Their studies: Daiichi Sankyo’s studies of Prostatic Neoplasms in search

Breast Neoplasms2 of 3 · compare here

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

–

Daiichi Sankyo in Breast Neoplasms: 3 programs

  1. trastuzumab deruxtecanphase 3
  2. datopotamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Breast Neoplasms in search

Renal Insufficiency2 of 3 · compare here

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

–

Daiichi Sankyo in Renal Insufficiency: 1 program

  1. olomorasibphase 2

Their studies: Daiichi Sankyo’s studies of Renal Insufficiency in search

Renal Insufficiency, Chronic2 of 3 · compare here

AstraZeneca in Renal Insufficiency, Chronic: 8 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. Berzanoflastphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency, Chronic in search

Celltrion in Renal Insufficiency, Chronic: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Renal Insufficiency, Chronic in search

–
Stomach Neoplasms2 of 3 · compare here–

Daiichi Sankyo in Stomach Neoplasms: 1 program

  1. trastuzumab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Stomach Neoplasms in search

Heart Failure2 of 3 · compare here

AstraZeneca in Heart Failure: 6 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. balcinrenonephase 3
  4. Pexerelgonphase 2
  5. dapagliflozinapproved, new study

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Heart Failure in search

Celltrion in Heart Failure: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Heart Failure in search

–
Neoplasms2 of 3 · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

–

Daiichi Sankyo in Neoplasms: 1 program

  1. patritumab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Neoplasms in search

Endometrial Neoplasms2 of 3 · compare here

AstraZeneca in Endometrial Neoplasms: 4 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. puxitatug samrotecanphase 3
  4. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Endometrial Neoplasms in search

–

Daiichi Sankyo in Endometrial Neoplasms: 2 programs

  1. trastuzumab deruxtecanphase 3
  2. datopotamab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Endometrial Neoplasms in search

Neoplasm Metastasis2 of 3 · compare here

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

–
Multiple Myeloma2 of 3 · compare here

Celltrion in Multiple Myeloma: 1 program

  1. daratumumabphase 3

Their studies: Celltrion’s studies of Multiple Myeloma in search

–
Triple Negative Breast Neoplasms2 of 3 · compare here

AstraZeneca in Triple Negative Breast Neoplasms: 4 programs

  1. datopotamab deruxtecanphase 3
  2. capivasertibphase 3
  3. ceralasertibphase 3
  4. Actinium-225phase 3

Their studies: AstraZeneca’s studies of Triple Negative Breast Neoplasms in search

–

Daiichi Sankyo in Triple Negative Breast Neoplasms: 1 program

  1. datopotamab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Triple Negative Breast Neoplasms in search

Arthritis, Rheumatoid2 of 3 · compare here

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Celltrion in Arthritis, Rheumatoid: 2 programs

  1. CT-P13 SC Auto-Injectorphase 3
  2. ixekizumabphase 1

Their studies: Celltrion’s studies of Arthritis, Rheumatoid in search

–
Carcinoma, Renal Cell2 of 3 · compare here

AstraZeneca in Carcinoma, Renal Cell: 3 programs

  1. volrustomigphase 3
  2. Actinium-225phase 3
  3. casdatifanphase 1

Their studies: AstraZeneca’s studies of Carcinoma, Renal Cell in search

–

Daiichi Sankyo in Carcinoma, Renal Cell: 1 program

  1. raludotatug deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Carcinoma, Renal Cell in search

Amyloidosis2 of 3 · compare here

AstraZeneca in Amyloidosis: 2 programs

  1. cliramitugphase 3
  2. acoramidisapproved, new study

Their studies: AstraZeneca’s studies of Amyloidosis in search

Celltrion in Amyloidosis: 1 program

  1. daratumumabphase 3

Their studies: Celltrion’s studies of Amyloidosis in search

–
Cardiovascular Diseases2 of 3 · compare here

AstraZeneca in Cardiovascular Diseases: 2 programs

  1. laroprovstatphase 3
  2. balcinrenonephase 3

Their studies: AstraZeneca’s studies of Cardiovascular Diseases in search

–

Daiichi Sankyo in Cardiovascular Diseases: 1 program

  1. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Cardiovascular Diseases in search

Hematologic Neoplasms2 of 3 · compare here

AstraZeneca in Hematologic Neoplasms: 1 program

  1. capivasertibphase 3

Their studies: AstraZeneca’s studies of Hematologic Neoplasms in search

–

Daiichi Sankyo in Hematologic Neoplasms: 2 programs

  1. Anti-CD37/DXd Antibody-drug Conjugate DS3790phase 2
  2. Combination drugphase 2

Their studies: Daiichi Sankyo’s studies of Hematologic Neoplasms in search

Hepatic Insufficiency2 of 3 · compare here

AstraZeneca in Hepatic Insufficiency: 2 programs

  1. atirmociclibphase 2
  2. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Hepatic Insufficiency in search

–

Daiichi Sankyo in Hepatic Insufficiency: 1 program

  1. olomorasibphase 2

Their studies: Daiichi Sankyo’s studies of Hepatic Insufficiency in search

Lymphoma, Mantle-Cell2 of 3 · compare here

AstraZeneca in Lymphoma, Mantle-Cell: 2 programs

  1. pirtobrutinibphase 2
  2. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Mantle-Cell in search

Celltrion in Lymphoma, Mantle-Cell: 1 program

  1. daratumumabphase 3

Their studies: Celltrion’s studies of Lymphoma, Mantle-Cell in search

–
Ovarian Neoplasms2 of 3 · compare here

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

–

Daiichi Sankyo in Ovarian Neoplasms: 1 program

  1. raludotatug deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Ovarian Neoplasms in search

Urinary Bladder Neoplasms2 of 3 · compare here

AstraZeneca in Urinary Bladder Neoplasms: 2 programs

  1. datopotamab deruxtecanphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Urinary Bladder Neoplasms in search

–

Daiichi Sankyo in Urinary Bladder Neoplasms: 1 program

  1. datopotamab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Urinary Bladder Neoplasms in search

Colorectal Neoplasms2 of 3 · compare here

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

–

Daiichi Sankyo in Colorectal Neoplasms: 1 program

  1. olomorasibphase 2

Their studies: Daiichi Sankyo’s studies of Colorectal Neoplasms in search

Diabetes Mellitus, Type 12 of 3 · compare here

AstraZeneca in Diabetes Mellitus, Type 1: 1 program

  1. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 1 in search

Celltrion in Diabetes Mellitus, Type 1: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Diabetes Mellitus, Type 1 in search

–
Fallopian Tube Neoplasms2 of 3 · compare here

AstraZeneca in Fallopian Tube Neoplasms: 1 program

  1. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Fallopian Tube Neoplasms in search

–

Daiichi Sankyo in Fallopian Tube Neoplasms: 1 program

  1. raludotatug deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Fallopian Tube Neoplasms in search

Kidney Diseases2 of 3 · compare here

AstraZeneca in Kidney Diseases: 1 program

  1. zibotentanphase 3

Their studies: AstraZeneca’s studies of Kidney Diseases in search

Celltrion in Kidney Diseases: 1 program

  1. Amlodipinephase 3

Their studies: Celltrion’s studies of Kidney Diseases in search

–
Lipid Metabolism, Inborn Errors2 of 3 · compare here–

Celltrion in Lipid Metabolism, Inborn Errors: 1 program

  1. Ezetimibephase 3

Their studies: Celltrion’s studies of Lipid Metabolism, Inborn Errors in search

Daiichi Sankyo in Lipid Metabolism, Inborn Errors: 1 program

  1. Ezetimibeapproved, new study

Their studies: Daiichi Sankyo’s studies of Lipid Metabolism, Inborn Errors in search

Lung Neoplasms2 of 3 · compare here

AstraZeneca in Lung Neoplasms: 1 program

  1. osimertinibapproved, new study

Their studies: AstraZeneca’s studies of Lung Neoplasms in search

–

Daiichi Sankyo in Lung Neoplasms: 1 program

  1. raludotatug deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Lung Neoplasms in search

Precursor Cell Lymphoblastic Leukemia-Lymphoma2 of 3 · compare here

AstraZeneca in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. Menin Inhibitor AZD3632phase 2

Their studies: AstraZeneca’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Celltrion in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. daratumumabphase 3

Their studies: Celltrion’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Celltrion 6 of 15 · Daiichi Sankyo 14 of 20 programs (46 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).